Sarepta Therapeutics surges 32% on expanded FDA approval for Duchenne gene therapy
Sarepta Therapeutics (NASDAQ) saw its shares soar 32% at market open on Friday following the FDA’s expanded approval of...
Sarepta Therapeutics (NASDAQ) saw its shares soar 32% at market open on Friday following the FDA’s expanded approval of...